What’s Going on with Exicure Inc.?
Exicure Inc. (XCUR) announced today that the clinical-stage biotechnology firm has just signed an exclusive collaboration deal with Ipsen to “research, develop, and commercialize novel Spherical Nucleic Acids (SNAs)” as possible investigational therapies for Angelman syndrome and Huntington’s disease. Pre-market this morning, XCUR stock soared 31.11%, up to $1.77 a share.
What Does This Mean for XCUR?
“We are thrilled to partner with Ipsen, a leading global company with significant expertise and commitment to developing treatments for patients with rare neurological diseases,” Exicure CEO David Giljohann, Ph.D., explained. “In collaboration with Ipsen, we have the opportunity to apply our technology to Huntington's disease and Angelman syndrome … We believe our platform technology with its deep penetration and persistence of medicinal effect will allow Exicure and Ipsen to overcome challenges from first-generation oligonucleotides and bring new medicines to patients in need.”
The collaboration agreement will see Ipsen pay Exicure an upfront cash payment of $20m upon closing of the deal. Ipsen will get “exclusive options to license SNA-based therapeutics” coming from the Huntington’s disease and Angelman syndrome collaboration programs. Further milestone payments and tiered royalties are possible as well, should Ipsen choose to exercise this option.
XCUR has a Fundamental Rank of 84. Find out what this means to you and get the rest of the rankings on XCUR!
Exicure Inc is a clinical-stage biotechnology company that develops a new class of immunomodulatory and gene silencing drugs against validated targets. It uses a spherical nucleic acid technology platform to build a pipeline of products for a range of diseases with unmet medical needs. The company addresses diseases, such as oncology, immunology, and dermatology.
